Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Sanofi will host a conference call for the financial community on Monday June 24, 2013, at 700 AM CST (200 PM Paris Time). The call will include results from the ongoing EDITION phase 3 program for U300 as well as a status update on the fixed-ratio combination of insulin glargine and lixisenatide.

Dial-in numbers and the audio webcast link will be accessible via www.sanofi.com.Contacts:Corporate Media RelationsGlobal Diabetes CommunicationsMarisol PeronTilmann KiesslingTel.: +33 1 53 77 45 02Mobile: +49 17 26 15 92 91Mobile: +33 6 08 18 94 78E-mail: Tilmann.Kiessling@sanofi.com E-mail: marisol.peron@sanofi.com Investor RelationsUS Diabetes CommunicationsSebastien MartelSusan BrooksTel : +33 (0)1 53 77 45 45Tel : +1 (0) 908 981 65 66E-mail: IR@sanofi.comMobile: +1 (0) 201 572 49 94E-mail: Susan.Brooks@sanofi.com
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  The BioFusionary Corporation, Inc. (TBC), ... proprietary electromagnetic induction platform with aesthetic and surgical ... under which TBC will merge with ... an all-stock transaction. Upon completion of ... the Australian Stock Exchange under the code COT. ...
(Date:7/29/2014)... 29, 2014 Today, Frost & Sullivan ... Sullivan Best Practices Award for Customer Value Leadership. ... platform that connects digital health application developers, medical ... pharmaceutical companies, prevention and wellness companies, population health ... Each year, Frost & Sullivan presents this award ...
(Date:7/29/2014)... --  Health 2.0 announces Bernard Tyson , CEO ... Eric Topol , Patrick Soon-Shiong , and Samsung,s President ... Annual Fall Conference this coming Sept. 21-24 in ... is set to host the very first Wearable Tech Fashion ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The panel ...
Breaking Medicine Technology:The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3
(Date:7/29/2014)... CRN International has promoted a longtime executive ... Upton, an 11-year veteran at the radio marketing company, ... managing the day-to-day execution of all CRN client campaigns. ... all activities for CRN clients, which include some ... The department interfaces directly with clients, sets project timelines ...
(Date:7/29/2014)... Somerset, NJ (PRWEB) July 29, 2014 ... drug development solutions and advanced delivery technologies for ... that Dr. Jeff Browne, R&D Director and US ... the Bioavailability of Absorption-Limited Drugs with Lipid-Based Formulations ... 30th Annual Meeting of the Japan Society of ...
(Date:7/29/2014)... 2014 TMG Health, the leading ... health plans in the Medicare Advantage, Medicare Part ... held its annual Client Forum at its National ... theme, “Partners in Excellence: Navigating the Post-Reform Landscape ... leaders from TMG Health’s Client base of Health ...
(Date:7/29/2014)... According to an article in the Daily ... a 52 year old woman in India. The surgery took ... had no idea that she had such a large tumor ... for years, but did not connect it to a possible ... the massive uterine fibroid after Latha was admitted for heavy ...
(Date:7/29/2014)... 2014 “Our years of experience ... fail to insulate their homes properly simply due ... preventing heat transfer and conduction,” Clean Crawls says ... recently released an article explaining exactly how ... energy bills. , To contact Clean Crawls for ...
Breaking Medicine News(10 mins):Health News:CRN International Names New Director to Lead Client Services Department 2Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 2Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 3Health News:World’s Largest Uterine Fibroid Removed from Patient 2Health News:World’s Largest Uterine Fibroid Removed from Patient 3Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2
... some common symptoms, due to which physicians often tend to ... occurs when the tongue or throat muscles // relax too ... more than 50 times an hour during sleep, causing snoring ... seconds. The problem is twice as common in men, and ...
... who survive Hodgkin's disease are found to have a higher ... that is given for the same, a new research has ... lymph nodes and the other immune system organs. Researchers found ... breast cancer if they survived Hodgkin's lymphoma. Dr Lois B. ...
... National Hospital, Oslo and other collaborating Universities from many ... 20 years in 900 adults has found that // ... risk of oral cancer in smoking individuals by at ... of developing cardiovascular deaths, the study has found that ...
... worldwide are estimated to suffer from multiple sclerosis (MS), ... young adults, and has a significant impact on the ... an average reduction in relapse rates of 30% in ... to weekly., ,Data from the extension of a ...
... been a dream come true for the scientists who been ... Administration is expected to take an extra step ahead as ... cloned animals, as well as their offspring, are safe to ... to cloning techniques, with Canadian Scientists having proved themselves following ...
... answer for the prayers of millions of men suffering ... robotic arms promises sooner recovery, less pain, scarring and ... cancer is the second leading cause of death among ... Asian men. It is estimated that one in six ...
Cached Medicine News:Health News:Reversibility of symptoms of depression using CPAP in patients with obstructive sleep apnea 2Health News:NSAIDS, Reduces The Risk Of Oral Cancer But Causes Heart Attacks 2Health News:New Hope For Patients With Relapsing Multiple Sclerosis 2Health News:Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer 2
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Nucleus chopper. For bimanual nucleus division....
Medicine Products: